Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.36 |
| ▸ | CDK2 | P24941 | 5/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559504 | 0.90 | MAPK1 (0.39) | HCAR3CCNE1CDK2MAPK1RPS6KA1 | |
| SCHEMBL559821 | 0.84 | MAPK1 (0.45) | MAPK1RPS6KA1GAAALDH1A1 | |
| SCHEMBL558698 | 0.82 | AOC3 (0.35) | CCNE1CDK2AOC3MAPK1PARP14 | |
| SCHEMBL559742 | 0.76 | GSK3B (0.35) | AOC3MAPK1PARP14ALDH1A1 | |
| SCHEMBL559788 | 0.73 | BRD4 (0.41) | HCAR3MAPK1CCNT1 | |
| SCHEMBL559789 | 0.73 | BRD4 (0.41) | HCAR3MAPK1CCNT1 | |
| SCHEMBL559257 | 0.72 | BRD4 (0.36) | AOC3MAPK1RPS6KA1HSD17B10CCNT1 | |
| SCHEMBL559117 | 0.70 | CDK2 (0.39) | CCNE1CDK2AOC3MAPK1CCNT1 | |
| SCHEMBL15511646 | 0.69 | MAPK1 (0.55) | HCAR3CCNE1CDK2MAPK1RPS6KA1 | |
| SCHEMBL10206025 | 0.68 | MAPK8 (0.48) | CDK2CCNT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017506-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-07-10 | — | — | US | claimed |
| US-20170158687-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-06-08 | — | — | US | claimed |
| US-20150210647-A1 | ATX MODULATING AGENTS | BIOGEN MA, INC. | 2015-07-30 | — | — | US | claimed |
| EP-2877166-A1 | ATX MODULATING AGENTS | Biogen Idec MA Inc. (US) | 2015-06-03 | — | — | EP | claimed |
| WO-2014018881-A1 | ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-01-30 | — | — | WO | claimed |
| US-10017506-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-2877166-B1 | 1-[7-(cis-4-methyl-cyclohexyloxy)-8-trifluoromethyl-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid derivatives as autotaxin (ATX) modulators for treating inflammations and autoimmune disorders | BIOGEN MA INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170158687-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-06-08 | — | — | US | disclosed |
| US-9522889-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150210647-A1 | ATX MODULATING AGENTS | BIOGEN MA, INC. | 2015-07-30 | — | — | US | disclosed |
| EP-2877166-A1 | ATX MODULATING AGENTS | Biogen Idec MA Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014018881-A1 | ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2024342-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | Pfizer Products Incorporated (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | HCAR3 757/4885CCNE1 523/4885CDK2 125/4885 |
| US-20150210647-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | HCAR3 4391/4885CCNE1 2434/4885CDK2 1018/4885 |
| US-20170158687-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | HCAR3 4391/4885CCNE1 2434/4885CDK2 1018/4885 |
| US-10017506-B2 | ATX modulating agents | ENPP2, ATXN10, ATXN2 | HCAR3 4391/4885CCNE1 2434/4885CDK2 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.